Scenarios that move CRL
Charles River Laboratories International, Inc. Common Stock
Scenarios that move CRL: 18 analyses, 15 positive, 3 negative.
- · RARE's Fayuvi approval triggers second $203 million PRV sale — ▲ · impact +12 · confidence low · horizon quarters
- · Syndax stock falls 16% as Phase II fibrosis study misses primary goal — ▼ · impact -6 · confidence low · horizon quarters
- · Viking Therapeutics advances oral obesity drug to Phase III — ▲ · impact +16 · confidence low · horizon quarters
- · argenx meets primary endpoint in Phase II celiac disease study — ▲ · impact +6 · confidence low · horizon quarters
- · SRX Global SPV agrees to acquire CERo Therapeutics — ▲ · impact +7 · confidence low · horizon quarters
- · Vaxcyte prices concurrent stock, warrant and convertible note offerings — ▲ · impact +15 · confidence low · horizon quarters
- · Spyre Therapeutics prices $350 million public stock offering — ▲ · impact +8 · confidence low · horizon quarters
- · Novartis acquires Abogen in $7.8B RNA therapeutics deal — ▲ · impact +9 · confidence low · horizon quarters
- · United Therapeutics stock rises 12.6% in trading — ▲ · impact +6 · confidence low · horizon quarters
- · uniQure plunges after additional Huntington's disease study data — ▼ · impact -12 · confidence low · horizon quarters
- · Lilly reports strong weight loss results for new drug — ▲ · impact +26 · confidence low · horizon quarters
- · Kodiak Sciences shares soar 178% on positive wet AMD data — ▲ · impact +10 · confidence low · horizon quarters
- · Novo and Hengrui sign exclusive license for oral GLP-1/GIP drug — ▲ · impact +10 · confidence low · horizon quarters
- · Zymeworks updates 2026 guidance after Theravance acquisition — ▲ · impact +10 · confidence low · horizon quarters
- · ADARx Pharmaceuticals prices upsized $446.3 million initial public offering — ▲ · impact +18 · confidence low · horizon quarters
- · Satellos wins FDA IND clearance for Forazapadin in FSHD — ▲ · impact +8 · confidence low · horizon quarters
- · Viking Therapeutics stock skyrockets in Tuesday trading — ▲ · impact +18 · confidence low · horizon quarters
- · Sion cuts workforce nearly half after CF study failure — ▼ · impact -24 · confidence medium · horizon weeks